P14.09 BORTEM-17: A Phase IB/II Single-Arm, Control Non-Randomized, Multicentre, Open Label Clinical Trial for Recurrent Glioblastoma with unmethylated MGMT promoter (NCT03643549)

por Goplen, D, Rahman, M A, Arnesen, V S, Brekke, J, Simonsen, A, Andreas, W, Marienhagen, K, Oltedal, L, Haasz, J, Miletic, H, Solheim, T S, Brandal, P, Lie, S A, Chekenya, M
Publicado 2021